Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ikervis for Prophylactic Treatment in Cataract Surgery
NCT04812951Phase 1Completed
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Feb 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cyclosporine 2% ophthalmic solution in ocular surface disease (OSD) and ocular inflammation, sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Symptoms Assessment Questionnaire iN Dry Eye at 4 months. Started Feb 2021; status: completed.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
ocular surface disease (OSD)ocular inflammation
Beyond the preview
Go deeper on NCT04812951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812951.